IBCN 2020: Predictive and Prognostic Performance of IHC3 Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer

(UroToday.com) Celine Hardy, a Masters Student at Queen’s University, Kingston, Canada presented “Predictive and prognostic performance of IHC3 Immunohistochemistry-based molecular subtyping in muscle-invasive bladder cancer (MIBC).” 



The role of molecular subtypes of MIBC is becoming more defined, with prognostic and predictive capacity with regards to response to neoadjuvant chemotherapy.  However, these molecular techniques are expensive and complex, currently limited to investigational efforts.  Hardy et al investigated molecular subtyping of MIBC using a simplified IHC-based algorithm.  Their IHC panel includes GATA3, KRT5 and p16.  GATA3 and KRT5 discriminate basal and luminal subtypes, while p16 differentiates URO from genomically unstable molecular subtypes.  Prospective validation is necessary for this promising classification system, and the direct correlation of IHC marker expression to pathologic response and clinical outcomes would be relevant.

IBCN_2020_Hardy_1.png


Presented by: Celine Hardy, a Masters Student at Queen’s University, Kingston, Canada 

Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.